睿知中国医院研究地图
候选清单

正在招募鼻咽癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

ClinicalTrials.gov 上登记的一项鼻咽癌开放试验。牵头方不是本站收录的医院;本站收录的 14 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 14

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心重庆大学附属肿瘤医院Chongqing University Cancer Hospital重庆医院页面
  2. 研究中心中山大学附属第一医院First Affiliated Hospital of Sun Yat-sen University广州医院页面
  3. 研究中心西安交通大学第一附属医院First Affiliated Hospital of Xi'an Jiaotong University西安医院页面
  4. 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
  5. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  6. 研究中心临沂市肿瘤医院Linyi Cancer Hospital临沂医院页面
  7. 研究中心柳州市人民医院Liuzhou People's Hospital柳州医院页面
  8. 研究中心南昌大学第二附属医院Second Affiliated Hospital of Nanchang University南昌医院页面
  9. 研究中心中山大学孙逸仙纪念医院Sun Yat-sen Memorial Hospital广州医院页面
  10. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
  11. 研究中心天津医科大学总医院Tianjin Medical University General Hospital天津医院页面
  12. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
  13. 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面
  14. 研究中心武汉大学中南医院Zhongnan Hospital of Wuhan University武汉医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05956587,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Patients with histologically and/or cytologically confirmed locally advanced or metastatic solid tumors such as non-small cell lung cancer and nasopharyngeal carcinoma;

    入选标准第 5 条

  3. For stage 3 Cohort_A, patients with MET 14 exon skipping detected by gene sequencing report before signing informed consent;

    排除标准第 1 条

  4. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;

    入选标准第 9 条

    Had received immunotherapy and developed ≥ grade 3 irAE or ≥ grade 2 immune-related myocarditis;

    排除标准第 3 条

  5. ECOG 0 or 1;

    入选标准第 8 条

  6. No blood transfusion, no use of cell growth factors and/or platelet raising drugs within 14 days before the first use of the study drug, and the level of organ function must meet the requirements;

    入选标准第 11 条

    Coagulation function: international normalized ratio ≤1.5, and activated partial thromboplastin time≤1.5 ULN;

    入选标准第 12 条

  7. At least one measurable lesion meeting the RECIST v1.1 definition was required;

    入选标准第 7 条

  8. Other malignancies diagnosed within 5 years before the first dose;

    排除标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05956587,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Sign the informed consent form voluntarily and follow the protocol requirements;
  2. Gender is not limited;
  3. Age: ≥18 years old and ≤75 years old;
  4. Expected survival time ≥3 months;
  5. Patients with histologically and/or cytologically confirmed locally advanced or metastatic solid tumors such as non-small cell lung cancer and nasopharyngeal carcinoma;
  6. Consent to provide archival tumor tissue samples or fresh tissue samples from primary or metastatic lesions within 2 years;
  7. At least one measurable lesion meeting the RECIST v1.1 definition was required;
  8. ECOG 0 or 1;
  9. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
  10. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
  11. No blood transfusion, no use of cell growth factors and/or platelet raising drugs within 14 days before the first use of the study drug, and the level of organ function must meet the requirements;
  12. Coagulation function: international normalized ratio ≤1.5, and activated partial thromboplastin time≤1.5 ULN;
  13. Urinary protein ≤2+ or ≤1000mg/24h;
  14. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, serum or urine must be negative for pregnancy, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.

排除标准:Exclusion Criteria:

  1. For stage 3 Cohort_A, patients with MET 14 exon skipping detected by gene sequencing report before signing informed consent;
  2. Chemotherapy, biological therapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Oral drugs such as fluorouracil;
  3. Had received immunotherapy and developed ≥ grade 3 irAE or ≥ grade 2 immune-related myocarditis;
  4. Use of immunomodulatory drugs within 14 days before the first dose of study drug;
  5. History of severe heart disease;
  6. QT prolongation, complete left bundle branch block, III degree atrioventricular block;
  7. Systemic corticosteroids or immunosuppressive agents are required within 2 weeks before study dosing;
  8. Active autoimmune and inflammatory diseases;
  9. Other malignancies diagnosed within 5 years before the first dose;
  10. Hypertension poorly controlled by two antihypertensive drugs;
  11. Pulmonary disease was defined as grade ≥3 according to CTCAE v5.0; Patients with current or history of ILD;
  12. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;
  13. Patients with a large amount of serous cavity effusion, or serous cavity effusion with symptoms, or within 4 weeks before signing informed consent;
  14. Patients with active central nervous system metastases;
  15. Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any excipients of the test drug;
  16. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation;
  17. Human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection or hepatitis C virus infection;
  18. Active infection requiring systemic therapy;
  19. Had participated in another clinical trial within 4 weeks before the first dose;
  20. The investigator did not consider it appropriate to use other conditions for participation in the trial.

引自 ClinicalTrials.gov, NCT05956587, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05956587,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05956587